Analysed METAVIA INC (MTVA:NASDAQ) News Sources
MTVA: Phase 1 Part 3 16-Week Titration Study of DA-1726 to Initiate in April 2026…
31-03-2026
yahoo.com
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
10-04-2026
yahoo.com
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
11-05-2026
yahoo.com
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
14-05-2026
yahoo.com
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
18-05-2026
yahoo.com
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
20-05-2026
yahoo.com
What is the current price of METAVIA INC (MTVA:NASDAQ)?
The current price of METAVIA INC (MTVA:NASDAQ) is $3.34.
METAVIA INC (MTVA:NASDAQ) absolute price change since previous trading day?
The absolute price change of METAVIA INC (MTVA:NASDAQ) since the previous trading day is $0.37.
METAVIA INC (MTVA:NASDAQ) percentage price change since previous trading day?
The percentage price change of METAVIA INC (MTVA:NASDAQ) since the previous trading day is 12.4579%.
What is the most recent average sentiment score for METAVIA INC (MTVA:NASDAQ)?
The most recent average sentiment score for METAVIA INC (MTVA:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for METAVIA INC (MTVA:NASDAQ)?
The most recent sentiment for METAVIA INC (MTVA:NASDAQ) is .
SEC-8K** Filing Available For METAVIA INC (MTVA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.